STOCKHOLDERS' EQUITY (Tables)

3 Months Ended

Mar. 31, 2022

STOCKHOLDERS' EQUITY

Schedule of Stock option activity

			Weighted
		Weighted	average
		average	remaining	Aggregate
		exercise	contractual	Intrinsic
	Number of	price	life	value
	options	$	Years	$
Options outstanding at beginning of period	1,878,168	18.13	6.96	3,861
Options granted	396,050	7.41	—	—
Options exercised			—	—
Options expired	(70,711)	9.44	—	—
Options forfeited	(78,391)	15.82	—	—
Options outstanding at end of period	2,125,116	17.04	7.35	179
Options vested and expected to vest at end of period	1,942,997	16.20	7.03	178
Exercisable at end of period	728,983	21.68	5.50	176

Schedule of Restricted Stock option activity

NOTE 8: - STOCKHOLDERS' EQUITY (Cont.)

Transactions related to the grant of restricted shares to employees, directors, and non-employees under the above plans during the three-months period ended March 31, 2022, were as follows:

	Number of
	Restricted shares
Restricted shares outstanding at beginning of period	1,094,637
Restricted shares granted	149,550
Restricted shares forfeited	(9,568)
Restricted shares outstanding at end of period	1,234,619

Schedule of assumptions used to estimate the fair values of the options granted to employees, directors and non-employees

The following table presents the assumptions used to estimate the fair values of the options granted to employees, directors, and non-employees in the period presented:

	Three months ended
	March 31,
	2022		2021
	Unaudited
Volatility	91.11-91.40	%	94.73-111.82	%
Risk-free interest rate	1.89	%	0.11-0.96	%
Dividend yield	0	%	0	%
Expected life (years)	5.81-5.88		2.09-5.88

Schedule of Compensation cost

The total compensation cost related to all of the Company’s stock-based awards recognized during the three-month period ended March 31, 2022, and 2021 was comprised as follows:

	Three months ended
	March 31,
	2022		2021
	Unaudited
Cost of revenues	$	23	$	13
Research and development		1,488		414
Sales and marketing		1,651		1,035
General and administrative		2,181		2,976
Total stock-based compensation expenses	$	5,343	$	4,438